kras inhibitors epidemiology forecast

Key Highlights

• KRAS oncogene is the most commonly mutated isoform of RAS, accounting for 85% of RAS-driven human cancers.
• KRAS is the most frequently mutated of the three RAS genes, followed by NRAS and HRAS. KRAS mutations are commonly associated with several types of cancer, including pancreatic, CRC, lung adenocarcinomas, ovarian, and others.
• KRAS mutations are seen most frequently in CRC, followed by pancreatic cancer, followed by NSCLC and LGSOC, capturing the lowest patient share. The most frequent KRAS variant observed in NSCLC is G12C. In the United States, KRASG12C is present in ~37% of NSCLC cases. The highest rates of KRASG12D, i.e., ~42% and ~42%, were found in pancreatic cancer and LGSOC, respectively.
• The United States had the highest number of KRAS mutation cases in NSCLC among the 7MM. Approximately 46% of all KRAS mutation cases in NSCLC in the 7MM were reported in the United States.
• The G12D variant is especially found in pancreatic and ovarian cancers, which are often hard to treat, while the G12C mutation is more common in NSCLC.

DelveInsight’s “KRAS Inhibitors – Epidemiology Forecast – 2034” report delivers an in-depth understanding of KRAS Inhibitors, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

KRAS Inhibitors Understanding

KRAS Inhibitors Overview

KRAS belongs to a group of small GTP-binding proteins known as the RAS superfamily or RAS-like GTPases. RAS, an oncogene, functions as a signal transducer, important for regulating cell proliferation, differentiation, and survival in normal and malignant cells. The RAS-mitogen-activated protein kinase-ERK kinase-extracellular signal-related kinase (RAS-RAF-MEK-ERK) pathway is one of the best-characterized signal transduction pathways, and its aberrancies are commonly implicated in the development of multiple different cancer types. KRAS mutations are genetic alterations in the KRAS gene, which encodes a protein in cell signaling pathways. These mutations are commonly found in various types of cancer, including CRC, lung, and pancreatic cancer.

KRAS Inhibitors Diagnosis

KRAS mutation can be diagnosed by conducting genetic sequencing of the tumor tissue or with the help of a liquid biopsy.

The clinician typically initiates KRAS testing requests for a patient. Usually, the testing is performed on tumor tissue removed from the patient during a previous surgery or biopsy procedure. Typically, patients undergoing KRAS testing with high-stage tumors require adjuvant therapy. If metastatic disease is present, it is important to clarify that the sample needed for testing is not the primary tumor but a representative tissue sample from the metastatic lesion. DNA is usually extracted from FFPE tissue blocks. It is the pathologist’s responsibility to identify the best tumor section to be subjected to testing. This includes evaluation of the slide with cut tissue or the tissue block, followed by microdissection and macro dissection for tumor enrichment to eliminate portions of necrotic tumor and nonneoplastic tissue. Typically, tumor-enriched areas will have relatively easily identified histology and can be dissected away from benign tissue. This process is often aided by having the fixed tissue cut placed on an unstained slide and having a standard H&E-stained (hematoxylin and eosin) slide of the same tissue cut available for comparison.

Further details related to diagnosis will be provided in the report…

KRAS Inhibitors Epidemiology

The KRAS inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total incident cases of NSCLC, CRC, pancreatic cancer, and LGSOC, total KRAS incident cases in NSCLC, CRC, pancreatic cancer, and LGSOC, total KRAS variant cases in NSCLC, CRC, pancreatic cancer, and LGSOC in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2021 to 2034.

• The total KRAS-mutated cases in the 7MM comprised more than ~509,700 cases in 2024 and are projected to increase during the forecast period.
• Among the selected cancer types, the most KRAS mutant cases are found in Colorectal Cancer, followed by pancreatic cancer, NSCLC, and LGSOC. In the United States, there were about ~66,000 cases of KRAS mutant colorectal cancer in 2024.
• In Japan, the contribution of KRAS mutations is lower compared to Western countries like the United States and Europe.

KRAS Inhibitors Report Insights

• KRAS Inhibitors Report Insights
• Patient population
• Country-wise epidemiology distribution

KRAS Inhibitors Report Key Strengths

• Ten-year forecast
• 7MM coverage
• KRAS Inhibitors epidemiology segmentation

FAQs

• What are the disease risks, burdens, and unmet needs of KRAS inhibitors? What will be the growth opportunities across the 7MM concerning the patient population with KRAS inhibitors?
• What is the historical and forecasted KRAS inhibitors patient pool in the US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.